2015 ISAKOS Biennial Congress ePoster #423
Evaluation of Effect of Autologous Plasma (Platelet Rich and Platelet Poor) on Growth Characteristics of Primary Human Anterior Cruciate Ligament Cells in Culture Conditions
Mandeep S Dhillon, MS, FAMS, FRCS, Chandigarh INDIA
PGIMER, Chandigarh, Chandigarh, INDIA
FDA Status Not Applicable
Summary: There was minimal enhancement viability of cultured ACL cells using of two concentrations of PRP as well as PPP in different subgroups, nor did it reduce the rate of cell death in all 3 subgroups
ePoster Not Provided
Platelet derived applications are now the vogue for many healing applications; Platelet-rich plasma (PRP) has the growth factors and Platelet poor plasma(PP) is only plasma proteins containing growth factors other than platelet derived. To see which would have more benefit, we compared the effects of autologous PRP & PPP on human ACL cell growth characteristics in culture conditions.
ACL remnants were collected from 11 patients during arthroscopic reconstruction; two different concentrations of PPP and PRP were prepared from 100ml venous blood of these patients. Cells were isolated, identified morphologically and cultured in RPMI Hepes media also containing FBS (fetal bovine serum), 25 mcg ascorbic acid, L-glutamine and gentamycin for 24-48 hours, and divided into following groups. Group A (10% fetal calf serum+ ACL cells+ media, control), Groups B contained 5% PRP, Group C 5% PPP, and group D 10% PRP. Cell viability was assayed by MTT & Annexin V assay and DNA content by propidium iodide staining and flow cytometry.
Analysis of cultured cells in all 6 groups showed that PRP (5% or 10%) increased viability of ACL cells only in 4 of 11 donor samples and promoted cell proliferation in 8 of 11 donor samples; 10% PRP was more effective than 5% PRP, but the difference was insignificant. 5% PPP had no significant effect on cell viability, but DNA content (cell proliferation) was increased in 5 of 11 samples compared to controls, indicating some enhancing effect, contributed by non-platelet derived growth-factors. There was no significant effect of either PRP or PPP in preventing cell death (depicted by apoptosis rate).
PRP has a limited enhancing effect on ACL cell viability, but larger, more controlled studies are needed to confirm its clinical utility.